Base de dados : MEDLINE
Pesquisa : C08.618.020 [Categoria DeCS]
Referências encontradas : 3359 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 336 ir para página                         

  1 / 3359 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29366758
[Au] Autor:Yuhong L; Tana W; Zhengzhong B; Feng T; Qin G; Yingzhong Y; Wei G; Yaping W; Langelier C; Rondina MT; Ge RL
[Ad] Endereço:Research Center for High Altitude Medicine, Qinghai University, Xining 810001, China; Department of Respiratory Medicine, The Affiliated Hospital of Qinghai University, Xining 810001, China.
[Ti] Título:Transcriptomic profiling reveals gene expression kinetics in patients with hypoxia and high altitude pulmonary edema.
[So] Source:Gene;651:200-205, 2018 Apr 20.
[Is] ISSN:1879-0038
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: High altitude pulmonary edema (HAPE) is a life threatening condition occurring in otherwise healthy individuals who rapidly ascend to high altitude. However, the molecular mechanisms of its pathophysiology are not well understood. The objective of this study is to evaluate differential gene expression in patients with HAPE during acute illness and subsequent recovery. METHODS: Twenty-one individuals who ascended to an altitude of 3780 m were studied, including 12 patients who developed HAPE and 9 matched controls without HAPE. Whole-blood samples were collected during acute illness and subsequent recovery for analysis of the expression of hypoxia-related genes, and physiologic and laboratory parameters, including mean pulmonary arterial pressure (mPAP), heart rate, blood pressure, and arterial oxygen saturation (SpO ), were also measured. RESULTS: Compared with control subjects, numerous hypoxia-related genes were up-regulated in patients with acute HAPE. Gene network analyses suggested that HIF-1α played a central role in acute HAPE by affecting a variety of hypoxia-related genes, including BNIP3L, VEGFA, ANGPTL4 and EGLN1. Transcriptomic profiling revealed the expression of most HAPE-induced genes was restored to a normal level during the recovery phase except some key hypoxia response factors, such asBNIP3L, EGR1, MMP9 and VEGF, which remained persistently elevated. CONCLUSIONS: Differential expression analysis of hypoxia-related genes revealed distinct molecular signatures of HAPE during acute and recovery phases. This study may help us to better understand HAPE pathogenesis and putative targets for further investigation and therapeutic intervention.
[Mh] Termos MeSH primário: Doença da Altitude/genética
Hipertensão Pulmonar/genética
Edema Pulmonar/genética
[Mh] Termos MeSH secundário: Lesão Pulmonar Aguda/etiologia
Lesão Pulmonar Aguda/genética
Adulto
Estudos de Casos e Controles
Estudos de Coortes
Perfilação da Expressão Gênica
Seres Humanos
Regulação para Cima
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE


  2 / 3359 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29297216
[Au] Autor:Sorokina TS
[Ti] Título:"The Great Silk Road" and the First Description of Hypoxia.
[So] Source:Vesalius;22(2 Suppl):53-8, 2016 Dec.
[Is] ISSN:1373-4857
[Cp] País de publicação:Belgium
[La] Idioma:eng
[Ab] Resumo:The first written reports about the effect of high-altitude air on the human organism in Ancient China (the 30s BC) and in South America during the conquest (late XVI century) are discussed in this paper.
[Mh] Termos MeSH primário: Doença da Altitude/história
Colonialismo/história
Comércio/história
[Mh] Termos MeSH secundário: Doença da Altitude/etiologia
China
História do Século XVI
História Antiga
Seres Humanos
Peru
Seda/economia
Seda/história
[Pt] Tipo de publicação:HISTORICAL ARTICLE; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Silk)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180212
[Lr] Data última revisão:
180212
[Sb] Subgrupo de revista:QIS
[Da] Data de entrada para processamento:180104
[St] Status:MEDLINE


  3 / 3359 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29100088
[Au] Autor:Crawford JE; Amaru R; Song J; Julian CG; Racimo F; Cheng JY; Guo X; Yao J; Ambale-Venkatesh B; Lima JA; Rotter JI; Stehlik J; Moore LG; Prchal JT; Nielsen R
[Ad] Endereço:Department of Integrative Biology, University of California, Berkeley, Berkeley, CA 94702, USA.
[Ti] Título:Natural Selection on Genes Related to Cardiovascular Health in High-Altitude Adapted Andeans.
[So] Source:Am J Hum Genet;101(5):752-767, 2017 Nov 02.
[Is] ISSN:1537-6605
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The increase in red blood cell mass (polycythemia) due to the reduced oxygen availability (hypoxia) of residence at high altitude or other conditions is generally thought to be beneficial in terms of increasing tissue oxygen supply. However, the extreme polycythemia and accompanying increased mortality due to heart failure in chronic mountain sickness most likely reduces fitness. Tibetan highlanders have adapted to high altitude, possibly in part via the selection of genetic variants associated with reduced polycythemic response to hypoxia. In contrast, high-altitude-adapted Quechua- and Aymara-speaking inhabitants of the Andean Altiplano are not protected from high-altitude polycythemia in the same way, yet they exhibit other adaptive features for which the genetic underpinnings remain obscure. Here, we used whole-genome sequencing to scan high-altitude Andeans for signals of selection. The genes showing the strongest evidence of selection-including BRINP3, NOS2, and TBX5-are associated with cardiovascular development and function but are not in the response-to-hypoxia pathway. Using association mapping, we demonstrated that the haplotypes under selection are associated with phenotypic variations related to cardiovascular health. We hypothesize that selection in response to hypoxia in Andeans could have vascular effects and could serve to mitigate the deleterious effects of polycythemia rather than reduce polycythemia itself.
[Mh] Termos MeSH primário: Adaptação Fisiológica/genética
Doença da Altitude/genética
Sistema Cardiovascular/fisiopatologia
Seleção Genética/genética
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Altitude
Feminino
Estudo de Associação Genômica Ampla/métodos
Haplótipos/genética
Insuficiência Cardíaca/genética
Seres Humanos
Hipóxia/genética
Masculino
Meia-Idade
Policitemia/genética
Polimorfismo de Nucleotídeo Único/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171118
[Lr] Data última revisão:
171118
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171104
[St] Status:MEDLINE


  4 / 3359 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28953687
[Au] Autor:Rong H; He X; Zhu L; Zhu X; Kang L; Wang L; He Y; Yuan D; Jin T
[Ad] Endereço:aKey Laboratory of Molecular Mechanism and Intervention Research for Plateau Diseases of Tibet Autonomous Region bKey Laboratory of High Altitude Environment and Genes Related to Diseases of Tibet Autonomous Region cKey Laboratory for Basic Life Science Research of Tibet Autonomous Region, School of Medicine, Xizang Minzu University, Xianyang, Shaanxi dSchool of Life Science, Northwest University, Xi'an, China.
[Ti] Título:Association between regulator of telomere elongation helicase1 (RTEL1) gene and HAPE risk: A case-control study.
[So] Source:Medicine (Baltimore);96(39):e8222, 2017 Sep.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:High altitude pulmonary edema (HAPE) is a paradigm of pulmonary edema. Mutations in regulator of telomere elongation helicase1 (RTEL1) represent an important contributor to risk for pulmonary fibrosis. However, little information is found about the association between RTEL1 and HAPE risk. The present study was undertaken to tentatively explore the potential relation between single-nucleotide polymorphisms (SNPs) in RTEL1 and HAPE risk in Chinese Han population. A total of 265 HAPE patients and 303 healthy controls were included in our case-control study. Four SNPs in RTEL1 were selected and genotyped using the Sequenom MassARRAY method. Odds ratios (ORs) and 95% confidence intervals (95% CIs) were calculated by unconditional logistic regression with adjustment for gender and age. All P values were Bonferroni corrected, and statistical significance was set at P < .0025 (.05/20). In allelic model analysis, we found that the allele "G" of rs6089953 and rs6010621 and the allele "A" of rs2297441 were associated with decreased risk of HAPE. In the genetic model analysis, we found that rs6010621, rs6089953, and rs2297441 were relevant to decreased HAPE risk under dominant model (rs6010621: OR = 0.55; 95% CI = 0.39-0.78; P = .001; rs6089953: OR = 0.68; 95% CI = 0.48-0.96; P = .027; rs2297441: OR = 0.63; 95% CI = 0.45-0.89; P = .008, respectively) and additive model (rs6010621: OR = 0.51; 95% CI = 0.46-0.81; P < .001; rs6089953: OR = 0.72; 95% CI = 0.55-0.95; P = .022; rs2297441: OR = 0.73; 95% CI = 0.57-0.95; P = .019, respectively). SNPs rs6010621 remained significant after Bonferroni correction (P < .0025). In addition, haplotype "GG, GT, AT" of rs6089953-rs6010621 were detected significantly associated with HAPE risk (P < .05), haplotype "GG" remained significant after Bonferroni correction (P < .0025). Our findings provide new evidence for the association between SNPs in RTEL1 and a decreased risk HAPE in the Chinese population. The results need further confirmation.
[Mh] Termos MeSH primário: Doença da Altitude
Hipertensão Pulmonar
[Mh] Termos MeSH secundário: Adulto
Doença da Altitude/epidemiologia
Doença da Altitude/genética
Estudos de Casos e Controles
China/epidemiologia
DNA Helicases/genética
Feminino
Predisposição Genética para Doença
Seres Humanos
Hipertensão Pulmonar/epidemiologia
Hipertensão Pulmonar/genética
Masculino
Mutação
Polimorfismo de Nucleotídeo Único
Fatores de Proteção
Medição de Risco/métodos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EC 3.6.1.- (RTEL1 protein, human); EC 3.6.4.- (DNA Helicases)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170928
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008222


  5 / 3359 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28832689
[Au] Autor:Cheng FY; Jeng MJ; Lin YC; Wang SH; Wu SH; Li WC; Huang KF; Chiu TF
[Ad] Endereço:Institute of Emergency and Critical Care Medicine, School of Medicine, National Yang-Ming University, Taipei, Taiwan.
[Ti] Título:Incidence and severity of acute mountain sickness and associated symptoms in children trekking on Xue Mountain, Taiwan.
[So] Source:PLoS One;12(8):e0183207, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Acute mountain sickness (AMS) occurs in non-acclimatized people after an acute ascent to an altitude of 2,500 m or higher. The aim of this study was to examine the incidence and severity of AMS and associated symptoms in children. METHODS: The prospective observational study included 197 healthy, non-acclimatized 11 and 12-year-old children trekking the round-trip from the trailhead to the summit of Xue Mountain, Taiwan (2,179 m to 3,886 m) over 3 days. AMS was evaluated at Qika Hut (2,460 m) on Day 1, at Sanliujiu Hut on Day 2 (3,100 m), and at the same altitude (3,100 m) after reaching the summit on Day 3. We used the Lake Louise Score (LLS) to diagnose AMS and record daily AMS-associated symptoms. We gave acetazolamide to children with mild to moderate AMS. Dexamethasone was reserved for individuals suffering from severe AMS. Acetaminophen was administrated to children with headache, and metoclopramide for those with nausea or vomiting. RESULTS: There were 197 subjects eligible for analysis. The overall incidence of AMS was 40.6%, which was higher in males and in subjects with a higher body mass index (BMI) (p < 0.05). The prevalence of AMS on Day 1 was 5.6%, which was significantly lower than that on Day 2 (29.4%) and Day 3 (23.4%). The mean LLS of all subjects was 1.77 ± 2.08. The overall incidence of severe AMS (LLS ≥ 5) was 12.5%. The mean LLS of the AMS group (3.02 ± 2.46) was significantly higher than that of the non-AMS group (0.92 ± 1.16, p < 0.001). Among the AMS group, the mean LLS was 1.00 ± 1.55 on Day 1, 4.09 ± 1.97 on Day 2, and 3.98 ± 2.42 on Day 3. The most common symptom was sleep disturbance followed by dizziness, and headache. The prevalence of headache was 46.2% on Day 2 at 3,100 m, and 31.3% on Day 3 at the same altitude after climbing the summit (3,886 m). Males experienced significantly more headache and fatigue than females (p < 0.05). The LLS and prevalence of all AMS symptoms were significantly higher in the AMS than the non-AMS group (p < 0.05). CONCLUSIONS: The AMS incidence among children trekking to Xue Mountain was 40.6%. AMS is common and mostly manifests as mild symptoms. Gender (male) and a higher BMI could be considered two independent risk factors of higher AMS incidence. Sleep disturbance is the most common symptom, and the lower prevalence of headache on Day 3 may be due to the effects of medication and/or acclimatization.
[Mh] Termos MeSH primário: Doença da Altitude/epidemiologia
[Mh] Termos MeSH secundário: Doença Aguda
Criança
Feminino
Seres Humanos
Incidência
Masculino
Estudos Prospectivos
Taiwan/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170824
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0183207


  6 / 3359 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28675800
[Au] Autor:Cooper MG; Street NE
[Ad] Endereço:Senior Anaesthetist, Department of Anaesthesia, The Children's Hospital at Westmead, Sydney, New South Wales.
[Ti] Título:High altitude hypoxia, a mask and a Street. Donation of an aviation BLB oxygen mask apparatus from World War 2.
[So] Source:Anaesth Intensive Care;45(7):45-48, 2017 03.
[Is] ISSN:0310-057X
[Cp] País de publicação:Australia
[La] Idioma:eng
[Ab] Resumo:The history of hypoxia prevention is closely inter-related with high altitude mountain and aviation physiology. One pioneering attempt to overcome low inspired oxygen partial pressures in aviation was the BLB mask-named after the three designers-Walter M Boothby, W Randolph Lovelace II and Arthur H Bulbulian. This mask and its variations originated just prior to World War 2 when aircraft were able to fly higher than 10,000 feet and pilot hypoxia affecting performance was an increasing problem. We give a brief description of the mask and its designers and discuss the donation of a model used by the British War Office in October 1940 and donated to the Harry Daly Museum at the Australian Society of Anaesthetists by the family of Dr Fred Street. Dr Street was a pioneering paediatric surgeon in Australia and served as a doctor in the Middle East and New Guinea in World War 2. He received the Military Cross.
[Mh] Termos MeSH primário: Doença da Altitude/prevenção & controle
Aviação
Hipóxia/prevenção & controle
Máscaras/história
Guerra
[Mh] Termos MeSH secundário: História do Século XIX
História do Século XX
Seres Humanos
[Pt] Tipo de publicação:BIOGRAPHY; HISTORICAL ARTICLE; JOURNAL ARTICLE
[Ps] Nome de pessoa como assunto:Boothby WM; Lovelace II RW; Bulbulian AH
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170705
[St] Status:MEDLINE


  7 / 3359 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:28653390
[Au] Autor:Nieto Estrada VH; Molano Franco D; Medina RD; Gonzalez Garay AG; Martí-Carvajal AJ; Arevalo-Rodriguez I
[Ad] Endereço:Department of Critical Care Medicine, Hospital de San José, Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia.
[Ti] Título:Interventions for preventing high altitude illness: Part 1. Commonly-used classes of drugs.
[So] Source:Cochrane Database Syst Rev;6:CD009761, 2017 06 27.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: High altitude illness (HAI) is a term used to describe a group of cerebral and pulmonary syndromes that can occur during travel to elevations above 2500 metres (8202 feet). Acute hypoxia, acute mountain sickness (AMS), high altitude cerebral oedema (HACE) and high altitude pulmonary oedema (HAPE) are reported as potential medical problems associated with high altitude. In this review, the first in a series of three about preventive strategies for HAI, we assess the effectiveness of six of the most recommended classes of pharmacological interventions. OBJECTIVES: To assess the clinical effectiveness and adverse events of commonly-used pharmacological interventions for preventing acute HAI. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE (OVID), Embase (OVID), LILACS and trial registries in January 2017. We adapted the MEDLINE strategy for searching the other databases. We used a combination of thesaurus-based and free-text terms to search. SELECTION CRITERIA: We included randomized-controlled and cross-over trials conducted in any setting where commonly-used classes of drugs were used to prevent acute HAI. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures as expected by Cochrane. MAIN RESULTS: We included 64 studies (78 references) and 4547 participants in this review, and classified 12 additional studies as ongoing. A further 12 studies await classification, as we were unable to obtain the full texts. Most of the studies were conducted in high altitude mountain areas, while the rest used low pressure (hypobaric) chambers to simulate altitude exposure. Twenty-four trials provided the intervention between three and five days prior to the ascent, and 23 trials, between one and two days beforehand. Most of the included studies reached a final altitude of between 4001 and 5000 metres above sea level. Risks of bias were unclear for several domains, and a considerable number of studies did not report adverse events of the evaluated interventions. We found 26 comparisons, 15 of them comparing commonly-used drugs versus placebo. We report results for the three most important comparisons: Acetazolamide versus placebo (28 parallel studies; 2345 participants)The risk of AMS was reduced with acetazolamide (risk ratio (RR) 0.47, 95% confidence interval (CI) 0.39 to 0.56; I = 0%; 16 studies; 2301 participants; moderate quality of evidence). No events of HAPE were reported and only one event of HACE (RR 0.32, 95% CI 0.01 to 7.48; 6 parallel studies; 1126 participants; moderate quality of evidence). Few studies reported side effects for this comparison, and they showed an increase in the risk of paraesthesia with the intake of acetazolamide (RR 5.53, 95% CI 2.81 to 10.88, I = 60%; 5 studies, 789 participants; low quality of evidence). Budenoside versus placebo (2 parallel studies; 132 participants)Data on budenoside showed a reduction in the incidence of AMS compared with placebo (RR 0.37, 95% CI 0.23 to 0.61; I = 0%; 2 studies, 132 participants; low quality of evidence). Studies included did not report events of HAPE or HACE, and they did not find side effects (low quality of evidence). Dexamethasone versus placebo (7 parallel studies; 205 participants)For dexamethasone, the data did not show benefits at any dosage (RR 0.60, 95% CI 0.36 to 1.00; I2 = 39%; 4 trials, 176 participants; low quality of evidence). Included studies did not report events of HAPE or HACE, and we rated the evidence about adverse events as of very low quality. AUTHORS' CONCLUSIONS: Our assessment of the most commonly-used pharmacological interventions suggests that acetazolamide is an effective pharmacological agent to prevent acute HAI in dosages of 250 to 750 mg/day. This information is based on evidence of moderate quality. Acetazolamide is associated with an increased risk of paraesthesia, although there are few reports about other adverse events from the available evidence. The clinical benefits and harms of other pharmacological interventions such as ibuprofen, budenoside and dexamethasone are unclear. Large multicentre studies are needed for most of the pharmacological agents evaluated in this review, to evaluate their effectiveness and safety.
[Mh] Termos MeSH primário: Acetazolamida/uso terapêutico
Doença da Altitude/prevenção & controle
Edema Encefálico/prevenção & controle
Budesonida/uso terapêutico
Inibidores da Anidrase Carbônica/uso terapêutico
Dexametasona/uso terapêutico
Glucocorticoides/uso terapêutico
Hipertensão Pulmonar/prevenção & controle
[Mh] Termos MeSH secundário: Acetazolamida/efeitos adversos
Adolescente
Adulto
Idoso
Doença da Altitude/complicações
Doença da Altitude/epidemiologia
Edema Encefálico/epidemiologia
Edema Encefálico/etiologia
Inibidores da Anidrase Carbônica/efeitos adversos
Dexametasona/efeitos adversos
Seres Humanos
Hipertensão Pulmonar/epidemiologia
Meia-Idade
Parestesia/induzido quimicamente
Viés de Publicação
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Carbonic Anhydrase Inhibitors); 0 (Glucocorticoids); 51333-22-3 (Budesonide); 7S5I7G3JQL (Dexamethasone); O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD009761.pub2


  8 / 3359 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28584018
[Au] Autor:Revera M; Salvi P; Faini A; Giuliano A; Gregorini F; Bilo G; Lombardi C; Mancia G; Agostoni P; Parati G; HIGHCARE Himalaya Investigators
[Ad] Endereço:From the Department of Cardiovascular, Neural, and Metabolic Sciences, Istituto Auxologico Italiano, Milan (M.R., P.S., A.F., A.G., F.G., G.B., C.L., G.M., G.P.); Department of Medicine and Surgery, Università di Milano-Bicocca, Italy (G.B., G.M., G.P.); Centro Cardiologico Monzino, Milan, Italy (P.
[Ti] Título:Renin-Angiotensin-Aldosterone System Is Not Involved in the Arterial Stiffening Induced by Acute and Prolonged Exposure to High Altitude.
[So] Source:Hypertension;70(1):75-84, 2017 Jul.
[Is] ISSN:1524-4563
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:This randomized, double-blind, placebo-controlled study was designed to explore the effects of exposure to very high altitude hypoxia on vascular wall properties and to clarify the role of renin-angiotensin-aldosterone system inhibition on these vascular changes. Forty-seven healthy subjects were included in this study: 22 randomized to telmisartan (age, 40.3±10.8 years; 7 women) and 25 to placebo (age, 39.3±9.8 years; 7 women). Tests were performed at sea level, pre- and post-treatment, during acute exposure to 3400 and 5400-m altitude (Mt. Everest Base Camp), and after 2 weeks, at 5400 m. The effects of hypobaric hypoxia on mechanical properties of large arteries were assessed by applanation tonometry, measuring carotid-femoral pulse wave velocity, analyzing arterial pulse waveforms, and evaluating subendocardial oxygen supply/demand index. No differences in hemodynamic changes during acute and prolonged exposure to 5400-m altitude were found between telmisartan and placebo groups. Aortic pulse wave velocity significantly increased with altitude ( <0.001) from 7.41±1.25 m/s at sea level to 7.70±1.13 m/s at 3400 m and to 8.52±1.59 m/s at arrival at 5400 m ( <0.0001), remaining elevated during prolonged exposure to this altitude (8.41±1.12 m/s; <0.0001). Subendocardial oxygen supply/demand index significantly decreased with acute exposure to 3400 m: from 1.72±0.30 m/s at sea level to 1.41±0.27 m/s at 3400 m ( <0.001), remaining significantly although slightly less reduced after reaching 5400 m (1.52±0.33) and after prolonged exposure to this altitude (1.53±0.25; <0.001). In conclusion, the acute exposure to hypobaric hypoxia induces aortic stiffening and reduction in subendocardial oxygen supply/demand index. Renin-angiotensin-aldosterone system does not seem to play any significant role in these hemodynamic changes. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrialsregister.eu/. Unique identifier: 2008-000540-14.
[Mh] Termos MeSH primário: Doença da Altitude
Aorta
Benzimidazóis
Benzoatos
Sistema Renina-Angiotensina
Rigidez Vascular
[Mh] Termos MeSH secundário: Adulto
Doença da Altitude/complicações
Doença da Altitude/metabolismo
Doença da Altitude/fisiopatologia
Doença da Altitude/prevenção & controle
Bloqueadores do Receptor Tipo 1 de Angiotensina II/administração & dosagem
Bloqueadores do Receptor Tipo 1 de Angiotensina II/farmacocinética
Aorta/efeitos dos fármacos
Aorta/metabolismo
Aorta/fisiopatologia
Benzimidazóis/administração & dosagem
Benzimidazóis/farmacocinética
Benzoatos/administração & dosagem
Benzoatos/farmacocinética
Disponibilidade Biológica
Análise da Demanda Biológica de Oxigênio/métodos
Feminino
Hemodinâmica/efeitos dos fármacos
Hemodinâmica/fisiologia
Seres Humanos
Masculino
Manometria/métodos
Meia-Idade
Análise de Onda de Pulso/métodos
Sistema Renina-Angiotensina/efeitos dos fármacos
Sistema Renina-Angiotensina/fisiologia
Resultado do Tratamento
Rigidez Vascular/efeitos dos fármacos
Rigidez Vascular/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Angiotensin II Type 1 Receptor Blockers); 0 (Benzimidazoles); 0 (Benzoates); U5SYW473RQ (telmisartan)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170824
[Lr] Data última revisão:
170824
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170607
[St] Status:MEDLINE
[do] DOI:10.1161/HYPERTENSIONAHA.117.09197


  9 / 3359 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28514605
[Au] Autor:West JB
[Ad] Endereço:From the Department of Medicine, University of California, San Diego, La Jolla.
[Ti] Título:Physiological Effects of Chronic Hypoxia.
[So] Source:N Engl J Med;376(20):1965-1971, 2017 May 18.
[Is] ISSN:1533-4406
[Cp] País de publicação:United States
[La] Idioma:eng
[Mh] Termos MeSH primário: Doença da Altitude/terapia
Fator 1 Induzível por Hipóxia/fisiologia
Hipóxia/fisiopatologia
Oxigênio/administração & dosagem
[Mh] Termos MeSH secundário: Ar Condicionado
Doença da Altitude/metabolismo
Doença da Altitude/fisiopatologia
Doença Crônica
Seres Humanos
Hipóxia/metabolismo
Fator 1 Induzível por Hipóxia/química
Fator 1 Induzível por Hipóxia/metabolismo
Oxigênio/metabolismo
Consumo de Oxigênio
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hypoxia-Inducible Factor 1); S88TT14065 (Oxygen)
[Em] Mês de entrada:1706
[Cu] Atualização por classe:170601
[Lr] Data última revisão:
170601
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170518
[St] Status:MEDLINE
[do] DOI:10.1056/NEJMra1612008


  10 / 3359 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28501324
[Au] Autor:Sun L; Ding MJ; Cai TC; Fan HJ; Gao HM; Zhang JP
[Ad] Endereço:Medical College of Chinese PLA, Chinese PLA General Hospital, 28#, Fu-Xing Road, Haidian District, Beijing 100853, China; Department of Respiratory and Critical Care Medicine of Ping Jin Hospital, Affiliated Hospital of Logistic University of Chinese People's Armed Police Force, China. Electronic ad
[Ti] Título:Using a new plateau hyperbaric chamber to alleviate high altitude hypoxia: Rabbit and human studies.
[So] Source:Am J Emerg Med;35(10):1536-1541, 2017 Oct.
[Is] ISSN:1532-8171
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To validate the effects of the new plateau hyperbaric chamber on alleviating high altitude hypoxia on Mount Kun Lun. METHODS: A prospective, controlled study of rabbits and adult volunteers was conducted at altitudes of 355, 2880 and 4532m. We obtained arterial blood samples from rabbits and volunteers before and after hyperbaric treatment. The respiratory rate, heart rate, and blood pressure (BP) of adult volunteers were monitored during hyperbaric treatment. RESULTS: The mean PaO levels of experimental group rabbits and volunteers increased significantly after 60min of hyperbaric treatment at 350, 2880 and 4532m. The mean PaCO and pH levels of rabbits were not significant different before and after hyperbaric treatment at each altitude. The mean PaCO and pH levels were not significant different at 355m in the human study. However, at 2880 and 4532m, pH fell with increasing PaCO levels in humans before and after hyperbaric treatment. CONCLUSIONS: The new multiplace plateau hyperbaric chamber may be used to alleviate plateau hypoxia by increasing patient PaO . However, its value in treating AMS must be confirmed in field conditions.
[Mh] Termos MeSH primário: Doença da Altitude/terapia
Oxigenação Hiperbárica/instrumentação
Hipóxia/terapia
Monitorização Fisiológica/métodos
Oxigênio/sangue
[Mh] Termos MeSH secundário: Doença da Altitude/sangue
Doença da Altitude/complicações
Animais
Modelos Animais de Doenças
Seres Humanos
Hipóxia/sangue
Hipóxia/etiologia
Coelhos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
S88TT14065 (Oxygen)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171012
[Lr] Data última revisão:
171012
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170515
[St] Status:MEDLINE



página 1 de 336 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde